JCS/T2D - A Diabetes Journey
LightNews LightNews
banner
jcst2d.bsky.social
JCS/T2D - A Diabetes Journey
@jcst2d.bsky.social
18 followers 3 following 130 posts
I draw on my professional expertise in data analysis and my personal health journey with Type 2 Diabetes to make technical information about T2D and obesity more accessible.
Posts Replies Media Videos
jcst2d.bsky.social
Professor Juleen R. Zierath’s work reveals how exercise improves glucose regulation by acting directly on skeletal muscle insulin resistance.

jcst2d.com/index.php/ar...

#MetabolicHealth #Type2Diabetes #ExerciseScience #InsulinResistance #DiabetesResearch
Professor Juleen R. Zierath. Photo by Ricky Molloy. Courtesy of Novo Nordisk Foundation.
January 13, 2026 at 12:14 AM
jcst2d.bsky.social
Hourly glucose visuals reduce anxiety by showing when patterns happen, not grading a single day. A more supportive way to understand CGM data.

jcst2d.com/index.php/ar...

#CGM #TimeInRange #DiabetesCare #DataVisualization #T2D
Bar chart showing hourly time in the 70–140 mg/dL range over the last seven days. Glucose stays near 100 percent overnight, dips from late morning through early evening, then returns to high in-range levels by late evening.
January 11, 2026 at 4:47 PM
jcst2d.bsky.social
Wegovy’s new oral GLP-1 pill is now available in the U.S., offering a daily option with strong results but strict dosing rules. Here’s what to know about real-world use and coverage.

jcst2d.com/index.php/ne...

#Wegovy #GLP1 #ObesityCare #WeightManagement #DiabetesCare
Image of 1.5 mg starter dose of Wegovy® pill. Courtesy of Novo Nordisk.
January 7, 2026 at 12:38 PM
jcst2d.bsky.social
FDA approves first oral GLP-1 for chronic weight management, reinforcing obesity as chronic disease and shifting care toward long-term treatment.

jcst2d.com/index.php/ne...

#ObesityCare #GLP1 #WeightManagement #FDAApproval #MetabolicHealth
Novo Nordisk flags. Courtesy of Novo Nordisk.
December 23, 2025 at 11:13 PM
jcst2d.bsky.social
Retatrutide shows up to 28.7% weight loss and major pain reduction in TRIUMPH-4, with a new but manageable dysesthesia signal and clear strategic positioning from Lilly.

jcst2d.com/index.php/ne...

#retatrutide #TRIUMPH4 #obesity #osteoarthritis #clinicaltrials
Eli Lilly logo
December 12, 2025 at 12:57 AM
jcst2d.bsky.social
Novo Nordisk files NDA for a higher 7.2 mg dose of Wegovy, supported by STEP UP trial results and an accelerated FDA review.

jcst2d.com/index.php/ne...

#Wegovy #Semaglutide #ObesityCare #GLP1 #ClinicalTrials
Novo Nordisk headquarters. Courtesy of News Øresund - Johan Wessman - Licensed under CC BY 3.0. Photo link: https://www.flickr.com/photos/newsoresund/29190030262.
November 28, 2025 at 4:19 PM
jcst2d.bsky.social
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes, with meaningful HbA1c and weight reductions. EVOKE findings add valuable insight for Alzheimer’s research.

jcst2d.com/index.php/ne...

#Diabetes #ObesityCare #GLP1 #Amycretin #ClinicalTrials
Martin Holst Lange, MD, PhD. Image courtesy of Novo Nordisk.
November 26, 2025 at 12:38 AM
jcst2d.bsky.social
Oral semaglutide did not slow Alzheimer’s progression in the EVOKE trials, despite favorable biomarker shifts.

jcst2d.com/index.php/ne...

#Semaglutide #EVOKETrials #Alzheimers #ClinicalTrialResults #MetabolicHealth
Novo Nordisk Flags. Courtesy of Novo Nordisk.
November 24, 2025 at 8:41 PM
jcst2d.bsky.social
Why Wegovy isn’t headed for OTC status—what the sources really say, why GLP-1 therapies don’t fit OTC criteria & why the conversation matters in obesity treatment.

jcst2d.com/index.php/ar...

#Wegovy #GLP1 #ObesityTreatment #DrugRegulation #MedicationSafety
Wegovy 2.4 mg pens
November 23, 2025 at 3:27 PM
jcst2d.bsky.social
Zealand Pharma paused dapiglutide after early data showed no advantage over newer incretin therapies. Focus shifts to programs with stronger potential.

jcst2d.com/index.php/ne...

#ObesityTreatment #GLP1 #Incretins #MetabolicHealth
Zealand Pharma logo
November 15, 2025 at 2:47 PM
jcst2d.bsky.social
Innovent’s mazdutide outperformed semaglutide in a key Phase 3 trial for type 2 diabetes and obesity. Expert commentary highlights trial design, metabolic mechanisms and next-gen incretin therapy questions.

jcst2d.com/index.php/ne...

#Mazdutide #Semaglutide #T2D #Obesity #IncretinTherapy
Innovent’s Mazdutide injection packaging and pens in 2 mg, 4 mg, and 6 mg doses, shown with labeled boxes and corresponding injection pens for type 2 diabetes and obesity treatment.
October 28, 2025 at 10:36 PM
jcst2d.bsky.social
New Lancet analysis shows semaglutide lowers major cardiovascular events by 20%, even in patients who lose little weight—highlighting benefits beyond fat loss.

jcst2d.com/index.php/ne...

#Semaglutide #SELECTTrial #HeartHealth #GLP1 #ObesityCare
Wegovy (semaglutide) 2.4 mg Pens
October 26, 2025 at 6:53 PM
jcst2d.bsky.social
Terns Pharmaceuticals has ended development of its oral GLP-1 obesity drug TERN-601 after modest Phase 2 results and new safety concerns. The company shifts focus to oncology with TERN-701 for leukemia.

jcst2d.com/index.php/ne...

#TernsPharma #Obesity #GLP1 #ClinicalTrials #DrugDevelopment
Terns Pharmaceuticals Logo
October 22, 2025 at 10:37 PM
jcst2d.bsky.social
FDA approves Novo Nordisk’s Rybelsus (oral semaglutide) to cut major heart risks in adults with type 2 diabetes. The SOUL trial showed a 14% reduction in cardiovascular events.

jcst2d.com/index.php/ne...

#Type2Diabetes #Rybelsus #HeartHealth #NovoNordisk
Oral semaglutide (Rybelsus). Courtesy of Novo Nordisk.
October 20, 2025 at 10:42 PM
jcst2d.bsky.social
Lilly’s oral GLP-1 orforglipron outshines Farxiga in Type 2 diabetes—a1C, weight, and heart metrics all improved.

jcst2d.com/index.php/ne...

#orforglipron #Farxiga #Type2Diabetes
Eli Lilly logo
October 17, 2025 at 10:38 PM
jcst2d.bsky.social
Novo Nordisk has resubmitted Awiqli® (insulin icodec) to the FDA for type 2 diabetes, offering fewer injections and a simpler treatment routine.

jcst2d.com/index.php/ne...

#NovoNordisk #Awiqli #Type2Diabetes #Insulin #DiabetesResearch
Awiqli® (insulin icodec) pen. Courtesy of Novo Nordisk Canada.
September 30, 2025 at 12:48 AM
jcst2d.bsky.social
Dexcom introduced Smart Basal at EASD 2025, a G7 app feature under FDA and CE Mark review that simplifies basal insulin initiation and adjustment.

jcst2d.com/index.php/ne...

#Dexcom #SmartBasal #EASD2025 #DiabetesCare #CGM
Illustration from the Dexcom G7 app showing the Dexcom Smart Basal feature. A hand holds a smartphone with a glucose trend line on the screen, next to a vial of insulin highlighted in a green circle. Text explains that glucose data is used to recommend a daily long-acting insulin dose.
September 22, 2025 at 11:21 PM
jcst2d.bsky.social
Novo Nordisk’s INFORM survey shows people on Wegovy® had 46% less “food noise,” plus boosts in mental health, habits & lifestyle. Sample size (550, mostly women, avg age 53) may limit generalizability.

jcst2d.com/index.php/ne...

#Wegovy #ObesityCare #PatientExperience
Novo Nordisk Flags. Courtesy of Novo Nordisk.
September 21, 2025 at 8:12 PM
jcst2d.bsky.social
Lilly’s oral GLP-1, orforglipron, delivers strong Phase 3 results with significant weight loss in obesity, superior A1C and weight outcomes vs oral semaglutide in type 2 diabetes.

jcst2d.com/index.php/ne...

#Orforglipron #ObesityTreatment #Type2Diabetes #WeightLoss
Eli Lilly Logo
September 21, 2025 at 6:31 PM
jcst2d.bsky.social
CGMs, wearables, biobanks, and registries show how personalized medicine in the Nordics connects to diabetes care and more broadly to medical care more broadly.

jcst2d.com/index.php/ar...

#Diabetes #CGM #HealthcareData #PersonalisedMedicine
Certificate of completion from Coursera for the course ‘Personalised Medicine from a Nordic Perspective,’ authorized by the University of Copenhagen and the University of Iceland, awarded to Jeffrey Smith on September 12, 2025.
September 14, 2025 at 6:13 PM
jcst2d.bsky.social
Novonesis and Novo Nordisk team up to explore how gut-targeted synbiotics might support metabolic health and tackle obesity and related conditions.

jcst2d.com/index.php/ne...

#Novonesis #NovoNordisk #GutMicrobiome #MetabolicHealth #ObesityPrevention
Logos of Novo Nordisk and Novonesis displayed over a blue-toned background of magnified gut microbiome imagery. Courtesy of Novonesis.
September 8, 2025 at 5:58 PM
jcst2d.bsky.social
CVS Caremark faces a class-action lawsuit over dropping Zepbound in favor of Wegovy. Plaintiffs cite differences in indications, patient tolerability, and outcomes; experts point out why the two drugs may be complementary.

jcst2d.com/index.php/ne...

#CVSCaremark #Wegovy #Zepbound #GLP1 #HealthLaw
Zepbound (tirzepatide) 5 mg pen
September 7, 2025 at 3:09 PM
jcst2d.bsky.social
Lilly ends two phase 2 trials of oral GLP-1 naperiglipron in type 2 diabetes and healthy adults. A study in obesity continues into 2026. The move reflects the market’s obesity focus, but the drug’s future remains uncertain.

jcst2d.com/index.php/ne...

#GLP1 #Obesity #DiabetesCare #ClinicalTrials
Eli Lilly Logo
September 4, 2025 at 10:21 PM
jcst2d.bsky.social
Novo Nordisk’s Wegovy cut the risk of heart attack, stroke or death by 57% compared to tirzepatide in a real-world study of people with obesity and cardiovascular disease.

jcst2d.com/index.php/ne...

#Wegovy #Mounjaro #Cardiovascular #Obesity #Diabetes
Wegovy 0.25 mg semaglutide injection pen for subcutaneous use, white body with teal and white label and gray cap.
August 31, 2025 at 6:19 PM
jcst2d.bsky.social
Teva's generic Saxenda (liraglutide) wins FDA approval, after its Victoza generic in 2024. Obesity drug market could nearly triple by 2030 with access, affordability & generics driving growth.

jcst2d.com/index.php/ne...

#Teva #GenericSaxenda #ObesityTreatment #FDAApproval #AccessToMedications
Teva logo
August 29, 2025 at 9:12 PM